# ClinicalTrials.gov record NCT06739122

> PeptideScanner retained ClinicalTrials.gov record NCT06739122 at 2026-08-13T05:52:27.010Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was dulaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06739122-dulaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-07
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06739122-dulaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct06739122-dulaglutide-v1.json
- Content SHA-256: `0d8c645c8a9426db4e105f9016ce6a67754619811690731a5ffd601a87d36529`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT06739122 ([`ctg-observation-nct06739122-2026-08-07-4e7b0d65d37a`](#source-ctg-observation-nct06739122-2026-08-07-4e7b0d65d37a))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06739122 at 2026-08-13T05:52:27.010Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was dulaglutide. ([`ctg-observation-nct06739122-2026-08-07-4e7b0d65d37a`](#source-ctg-observation-nct06739122-2026-08-07-4e7b0d65d37a))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06739122 at 2026-08-13T05:52:27.010Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was dulaglutide. ([`ctg-observation-nct06739122-2026-08-07-4e7b0d65d37a`](#source-ctg-observation-nct06739122-2026-08-07-4e7b0d65d37a))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06739122-2026-08-07-4e7b0d65d37a`](#source-ctg-observation-nct06739122-2026-08-07-4e7b0d65d37a))

## Sources

<a id="source-ctg-observation-nct06739122-2026-08-07-4e7b0d65d37a"></a>
- **ClinicalTrials.gov record NCT06739122 · retained source version 2026-08-07:4e7b0d65d37a4fd3262d4fc0128ccd28bc4df252f65638ac794eb649a8dcbe35** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06739122) (`ctg-observation-nct06739122-2026-08-07-4e7b0d65d37a`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06739122." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct06739122-dulaglutide-v1.json SHA-256: 0d8c645c8a9426db4e105f9016ce6a67754619811690731a5ffd601a87d36529.